Kobayashi Y, et al. (2005) SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 16, 237-43 16012755

This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.

Click on the protein name to open the protein page, and on the RSD number to open the site page.

Download

K186-ac - FOXO4 (mouse) ▲

Modsite: MLNPDGGkGGkAPRR SwissProt Entrez-Gene Orthologous residues FOXO4 (human): K186‑ac, FOXO4 (mouse): K186‑ac, FOXO4 (rat): K186‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  COS7 (fibroblast), HEK293T (epithelial), HeLa (cervical), Jurkat (T lymphocyte), Saos-2 (bone cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT1 (mouse) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes ACETYLTRANSFERASE p300 (mouse) transfection of wild-type enzyme DEACETYLASE SIRT1 (mouse) pharmacological activator of upstream enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nicotinamide increase resveratrol decrease H2O2 increase LY294002 increase Downstream Regulation Effect of modification (process):  transcription, inhibited

K189-ac - FOXO4 (mouse) ▲

Modsite: PDGGkGGkAPRRRAA SwissProt Entrez-Gene Orthologous residues FOXO4 (human): K189‑ac, FOXO4 (mouse): K189‑ac, FOXO4 (rat): K189‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  COS7 (fibroblast), HEK293T (epithelial), HeLa (cervical), Jurkat (T lymphocyte), Saos-2 (bone cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT1 (mouse) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes DEACETYLASE SIRT1 (mouse) pharmacological activator of upstream enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, co-immunoprecipitation ACETYLTRANSFERASE p300 (mouse) transfection of wild-type enzyme Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nicotinamide increase resveratrol decrease H2O2 increase LY294002 increase Downstream Regulation Effect of modification (process):  transcription, inhibited

K408-ac - FOXO4 (mouse) ▲

Modsite: GGMPSSSkLGTGVSL SwissProt Entrez-Gene Orthologous residues FOXO4 (human): K407‑ac, FOXO4 (mouse): K408‑ac, FOXO4 (rat): K408‑ac Characterization Methods used to characterize site in vivo:  immunoprecipitation, mutation of modification site, western blotting Disease tissue studied:  bone cancer, leukemia, T cell leukemia Relevant cell lines - cell types - tissues:  COS7 (fibroblast), HEK293T (epithelial), HeLa (cervical), Jurkat (T lymphocyte), Saos-2 (bone cell) Cellular systems studied:  cell lines Species studied:  human Enzymes shown to modify site in vitro:  Type Enzyme DEACETYLASE SIRT1 (mouse) Upstream Regulation Potential in vivo enzymes for site:  Type Enzyme Evidence Notes ACETYLTRANSFERASE p300 (mouse) transfection of wild-type enzyme DEACETYLASE SIRT1 (mouse) pharmacological activator of upstream enzyme, transfection of inactive enzyme, pharmacological inhibitor of upstream enzyme, transfection of wild-type enzyme, co-immunoprecipitation Treatments, proteins and their effect on site modification:  Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes nicotinamide increase resveratrol decrease H2O2 increase LY294002 increase Downstream Regulation Effect of modification (process):  transcription, inhibited